Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Libeweita [3][4][12]. Group 1: Scientific Contributions - Li Wenhui was the first to discover the receptor for the SARS virus and the hepatitis B virus, while Sui Jianhua was the first to design human antibodies against these viruses [3][4]. - During the COVID-19 pandemic, they collaborated on a broad-spectrum anti-COVID drug, although it was not developed further due to the pandemic's resolution [3][4]. - The monoclonal antibody drug Libeweita is set to be approved in January 2026, marking a significant milestone in the treatment of viral hepatitis [3][4]. Group 2: Personal and Professional Journey - Li and Sui met at Lanzhou University over 30 years ago and have since maintained a close professional relationship, often engaging in scientific debates that drive their research forward [11][15]. - They both pursued postdoctoral research at Harvard University, where their paths converged in the study of viral infections and antibody development [6][10]. - Their partnership is characterized by a seamless integration of their respective expertise, with Li focusing on the mechanisms of viral infections and Sui on antibody engineering [12][17]. Group 3: Company Formation and Vision - In 2015, they co-founded Huahui Anjian, a company aimed at developing innovative drugs for liver diseases, reflecting their shared scientific aspirations [16]. - Li primarily handles basic scientific discoveries while Sui manages the company's operations and clinical trials, showcasing their complementary roles [16][17]. - Their discussions often revolve around company matters, with a dynamic of questioning and critical thinking that fosters innovation [16][17].

Core Viewpoint - The article highlights the collaborative journey of two prominent scientists, Li Wenhui and Sui Jianhua, who have made significant contributions to the field of virology and antibody engineering, culminating in the development of the first monoclonal antibody drug for viral hepatitis, Lebevetab [1][2][6]. Group 1: Background and Education - Li Wenhui and Sui Jianhua met at Lanzhou University over 30 years ago and have since pursued parallel academic paths, including postdoctoral research at Harvard University [2][3]. - Their scientific collaboration began shortly after their marriage, leading to groundbreaking discoveries in the fields of SARS and hepatitis B [1][4]. Group 2: Research Contributions - Li Wenhui was the first to identify the receptor for the SARS virus, while Sui Jianhua developed the first human-derived antibody against SARS [3][6]. - Sui Jianhua discovered a broad-spectrum neutralizing antibody for the H1N1 influenza virus, which has implications for future antiviral treatments and vaccine development [5][6]. - In 2012, Li Wenhui identified the hepatitis B virus receptor, a significant breakthrough after decades of research [6][8]. Group 3: Company Formation and Drug Development - In 2015, the couple co-founded Huahui Anjian, a biopharmaceutical company aimed at developing innovative treatments for liver diseases [11][12]. - The company focuses on transforming scientific discoveries into practical applications, with Li Wenhui handling basic scientific research and Sui Jianhua managing operations and clinical trials [11][12]. Group 4: Personal Dynamics and Work Ethic - The couple is known for their intense debates on scientific topics, which they view as a means of intellectual growth rather than conflict [11][13]. - Their complementary skills—Li Wenhui's critical thinking and Sui Jianhua's practical application—allow for seamless collaboration in their research endeavors [8][11].

Core Insights - The study identifies multiple members of the low-density lipoprotein receptor (LDLR) family, specifically LRP1, LRP4, and VLDLR, as key receptors for the entry of the yellow fever virus (YFV) into human cells [2][6] - The research demonstrates that the soluble LRP4-Fc bait receptor can effectively neutralize YFV infection and reduce viral load in vivo [5][6] - The findings suggest that targeting LDLR family members could be significant for developing therapeutic strategies against YFV and other emerging viruses in the Orthoflavivirus genus [6] Summary by Sections - **Research Findings**: The study published in Nature reveals that LRP4 is a candidate receptor for YFV, and its knockout inhibits YFV infection, while its expression enhances it [5] - **Mechanism of Action**: LRP4 interacts with the viral envelope protein, facilitating YFV entry into cells. Other LDLR family members, LRP1 and VLDLR, also mediate YFV entry [5][6] - **Implications for Treatment**: The research indicates that LRP1-Fc, LRP4-Fc, and VLDLR-Fc bait proteins can protect mice from YFV and reduce liver damage, highlighting their potential in therapeutic applications [6]